TRISCEND II trial demonstrates superior clinical and quality-of-life benefits with Edwards EVOQUE system for severe tricuspid regurgitation
Edwards Lifesciences Corporation announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is… read more.
